| Literature DB >> 16478690 |
Volker Schnecke1, Jonas Boström.
Abstract
Novel starting points for drug discovery projects are generally found either by screening large collections of compounds or smaller more-focused libraries. Ideally, hundreds or even thousands of actives are initially found, and these need to be reduced to a handful of promising lead series. In several sequential steps, many actives are dropped and only some are followed up. Computational chemistry tools are used in this context to predict properties, cluster hits, design focused libraries and search for close analogues to explore the potential of hit series. At the end of hit-to-lead, the project must commit to one, or preferably a few, lead series that will be refined during lead optimization and hopefully produce a drug candidate. Striving for the best possible decision is crucial because choosing the wrong series is a costly one-way street.Mesh:
Year: 2006 PMID: 16478690 DOI: 10.1016/S1359-6446(05)03703-7
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851